Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 8/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5579386 | 1.00 | GAA (0.54) | GAAPOLBHDAC6HDAC1HDAC8 | |
| SCHEMBL5081576 | 0.87 | GAA (0.69) | GAAPOLBHDAC6HDAC1HDAC8 | |
| SCHEMBL5081579 | 0.87 | GAA (0.69) | GAAPOLBHDAC6HDAC1HDAC8 | |
| SCHEMBL5081975 | 0.82 | GAA (0.54) | GAAPOLBHDAC6HDAC1HDAC8 | |
| SCHEMBL5081584 | 0.82 | GAA (0.54) | GAAPOLBHDAC6HDAC1HDAC8 | |
| SCHEMBL5579644 | 0.82 | GAA (0.54) | GAAPOLBHDAC6HDAC1HDAC8 | |
| SCHEMBL14472937 | 0.80 | HDAC6 (0.55) | GAAPOLBHDAC6HDAC1HDAC8 | |
| SCHEMBL5579364 | 0.79 | MEN1 (0.43) | GAAHDAC6HDAC1HDAC8MAPT | |
| SCHEMBL5579368 | 0.79 | MEN1 (0.43) | GAAHDAC6HDAC1HDAC8MAPT | |
| SCHEMBL5077665 | 0.79 | MEN1 (0.43) | GAAHDAC6HDAC1HDAC8MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940805-A1 | BENZODIAZEPINE AND BENZOPIPERAZINE ANALOG INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2008-07-09 | — | — | EP | claimed |
| WO-2007022638-A1 | BENZODIAZEPINE AND BENZOPIPERAZINE ANALOG INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-03-01 | — | — | WO | claimed |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | METHYLGENE, INC. (CA) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | HDAC5, HDAC4, HDAC3 | GAA 1711/4885POLB 1435/4885HDAC6 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.